4.6 Article

Objective but Not Subjective Short Sleep Duration Associated with Increased Risk for Hypertension in Individuals with Insomnia

Journal

SLEEP
Volume 39, Issue 5, Pages 1037-1045

Publisher

OXFORD UNIV PRESS INC
DOI: 10.5665/sleep.5748

Keywords

hypertension; insomnia; polysomnography; prevalence; short sleep

Funding

  1. National Institute of Mental Health [R01 MH67057]
  2. Merck
  3. Philips Respironics
  4. Abbott
  5. Actelion
  6. Arena
  7. Astellas
  8. AstraZeneca
  9. Axiom
  10. BMS
  11. Cephalon
  12. Eli Lilly
  13. Evotec
  14. GlaxoSmithKline
  15. Jazz
  16. Johnson and Johnson
  17. King
  18. Kingsdown Inc.
  19. Neurocrine
  20. Neurogen
  21. Neuronetics
  22. NIH
  23. Novartis
  24. Organon
  25. Ortho-McNeil-Janssen
  26. Pfizer
  27. Roche
  28. Sanofi-Aventis
  29. Sepracor
  30. Somaxon
  31. Takeda
  32. Transcept

Ask authors/readers for more resources

Study Objectives: To examine the relationship between hypertension prevalence in individuals with insomnia who have short total sleep duration < 6 h or sleep duration >= 6 h, using both objective and subjective measures of total sleep duration. Methods: Using a cross-sectional, observational design, 255 adult volunteers (n = 165 women; 64.7%) meeting current diagnostic criteria for insomnia disorder (M-Age = 46.2 y, SDAge = 13.7 y) participated in this study at two large university medical centers. Two nights of polysomnography, 2 w of sleep diaries, questionnaires focused on sleep, medical, psychological, and health history, including presence/absence of hypertension were collected. Logistic regressions assessed the odds ratios of hypertension among persons with insomnia with short sleep duration < 6 h compared to persons with insomnia with a sleep duration >= 6 h, measured both objectively and subjectively. Results: Consistent with previous studies using objective total sleep duration, individuals with insomnia and short sleep duration < 6 h were associated with a 3.59 increased risk of reporting hypertension as a current medical problem as compared to individuals with insomnia with sleep duration >= 6 h. Increased risk for hypertension was independent of major confounding factors frequently associated with insomnia or hypertension. No significant risk was observed using subjectively determined total sleep time groups. Receiver operating characteristic curve analysis found that the best balance of sensitivity and specificity using subjective total sleep time was at a 6-h cutoff, but the area under the receiver operating characteristic curve showed low accuracy and did not have good discriminant value. Conclusions: Objectively measured short sleep duration increased the odds of reporting hypertension more than threefold after adjusting for potential confounders; this relationship was not significant for subjectively measured sleep duration. This research supports emerging evidence that insomnia with objective short sleep duration is associated with an increased risk of comorbid hypertension.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available